The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Kessler, Ute ^a,b   Vaaler, Arne E ^a,i   Schøyen, Helle ^b,c   Oedegaard, Ketil J ^a,b   Bergsholm, Per ^b,d   Andreassen, Ole A ^e,f   Malt, Ulrik F ^f,g   Morken, Gunnar ^h,i  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d Helse Førde Hospital Trust   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

ⁱ NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALIMEMAZINE; CHLORPROMAZINE; CHLORPROTHIXENE; IBUPROFEN; METOCLOPRAMIDE; MIANSERIN; MIDAZOLAM; OXAZEPAM; PARACETAMOL; PHENELZINE; THIOPENTAL; TRANYLCYPROMINE; ZOLPIDEM; PSYCHOTROPIC AGENT;

ADULT; ALGORITHM; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL PROTOCOL; COGNITION; DEPRESSION; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); NEUROPSYCHOLOGICAL TEST; NORWAY; PATIENT SAFETY; PREGNANCY; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SUICIDE; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; CLINICAL TRIAL; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TOXICITY; INTOXICATION; METHODOLOGY; MULTICENTER STUDY; PREGNANCY OUTCOME; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SUICIDE ATTEMPT; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; CLINICAL PROTOCOLS; COGNITION DISORDERS; DRUG RESISTANCE; DRUG TOXICITY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NORWAY; OVERDOSE; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; QUESTIONNAIRES; SUICIDE; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 77649325956     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-16     Document Type: Article

References (53)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51(1):8-19.
2. Simon GE, Ludman EJ, Bauer MS, Unutzer J, Operskalski B. Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry 2006, 63(5):500-508. 10.1001/archpsyc.63.5.500, 16651507.
3. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, Endicott J, Keller M. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003, 6(2):127-137. 10.1017/S1461145703003341, 12890306.
4. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003, 64(6):680-690. quiz 738-689.
5. Thase ME. Bipolar depression: issues in diagnosis and treatment. Harv Rev Psychiatry 2005, 13(5):257-271. 10.1080/10673220500326425, 16251165.
6. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007, 356(17):1711-1722. 10.1056/NEJMoa064135, 17392295.
7. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004, 161(2):217-222. 10.1176/appi.ajp.161.2.217, 14754766.
8. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60(11):1079-1088. 10.1001/archpsyc.60.11.1079, 14609883.
9. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162(7):1351-1360. 10.1176/appi.ajp.162.7.1351, 15994719.
10. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009, 194(1):4-9. 10.1192/bjp.bp.107.048504, 19118318.
11. Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, Wagner KD, Perlis RH. American Psychiatric Association: Practice Guidelines for the treatment of patients with bipolar disorder. 2002, Washington DC: American Psychiatric Association, 2.
12. Moksnes KM, Vatnaland T, Eri B, Torvik NH. Electroconvulsive therapy in the Ullevaal region of Oslo 1988-2002. Tidsskr Nor Laegeforen 2006, 126(13):1750-1753.
13. Weiner RD, Coffey CE, Fochtmann LJ, Greenberg RM, Isenberg KE, Kellner CH, Sackeim HA, Moench L. The Practice of Electroconvulsive Therapy. Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association 2001, Washington: American Psychiatric Association, 2.
14. Sienaert P, Peuskens J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder. Bipolar Disord 2006, 8(3):304-306. 10.1111/j.1399-5618.2006.00317.x, 16696836.
15. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006, 67(Suppl 6):16-22.
16. Sweeney JA, Kmiec JA, Kupfer DJ. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol Psychiatry 2000, 48(7):674-684. 10.1016/S0006-3223(00)00910-0, 11032979.
17. Holmes MK, Erickson K, Luckenbaugh DA, Drevets WC, Bain EE, Cannon DM, Snow J, Sahakian BJ, Manji HK, Zarate CA. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord 2008, 10(7):806-815. 10.1111/j.1399-5618.2008.00628.x, 2727596, 19032712.
18. Quraishi S, Frangou S. Neuropsychology of bipolar disorder: a review. J Affect Disord 2002, 72(3):209-226. 10.1016/S0165-0327(02)00091-5, 12450638.
19. McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry 2000, 57(5):438-444. 10.1001/archpsyc.57.5.438, 10807483.
20. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000, 57(5):425-434. 10.1001/archpsyc.57.5.425, 10807482.
21. Sackeim HA, Prudic J, Fuller R, Keilp J, Lavori PW, Olfson M. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology 2007, 32(1):244-254. 10.1038/sj.npp.1301180, 16936712.
22. Stern Y, Sano M, Pauson J, Mayeux R. Modified Mini-Mental State Examination: validity and reliability. Neurology 1987, 37:179.
23. National Institute for Clinical Excellence. Guidance on the Use of Electroconvulsive Therapy. 2003, London.
24. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med 2003, 35(1):2-11. 10.1080/07853890310004075, 12693607.
25. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003, 17(Suppl 1):S119-124. 10.1016/S0889-1591(02)00078-8, 12615197.
26. Sinha G. Inflamed brains can trigger the blues, studies suggest. Nat Med 2004, 10(10):1007. 10.1038/nm1004-1007b, 15459686.
27. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29(4-5):891-909. 10.1016/j.neubiorev.2005.03.023, 15885777.
28. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006, 90(2-3):263-267. 10.1016/j.jad.2005.11.015, 16410025.
29. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70(8):1078-1090. 10.4088/JCP.08r04505, 19497250.
30. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression?. Neurotoxicology 2009, 30(4):497-521. 10.1016/j.neuro.2009.03.004, 19477018.
31. Goodwin FK, Jamison KR. Maintenance Medical Treatment. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression 2007, 797-848. New York: Oxford University Press, Goodwin FK, Jamison KR, 2.
32. d'Elia G. Unilateral electroconvulsive therapy. Acta Psychiatr Scand Suppl 1970, 215:1-98.
33. Abrams R. Electroconvulsive therapy 2002, New York: Oxford University Press, 4.
34. d'Elia G. Present Practice of Electroconvulsive Therapy in Scandinavia. Arch Gen Psychiatry 1983, 40:577-581.
35. Goodwin FK, Jamison KR. Medical Treatment of Depression. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression 2007, 752-753. New York: Oxford University Press, Goodwin FK, Jamison KR, 2.
36. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33. quiz 34-57.
37. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP). 2002, New York: Biometrics Research, New York State Psychiatric Institute.
38. Post RM, Nolen WA, Kupka RW, Denicoff KD, Leverich GS, Keck PE, McElroy SL, Rush AJ, Suppes T, Altshuler LL, Frye MA, Grunze H, Walden J. The Stanley Foundation Bipolar Network I. Rationale and Methods. Br J Psychiatry 2001, 178(suppl 41):169-176.
39. Leverich GS, Nolen WA, Rush AJ, McElroy SL, Keck PE, Denicoff KD, Suppes T, Altshuler LL, Kupka R, Kramlinger KG, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord 2001, 67(1-3):33-44. 10.1016/S0165-0327(01)00430-X, 11869751.
40. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
41. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986, 18(1):65-87. 10.1016/0165-1781(86)90060-0, 3737788.
42. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73(3):159-171. 10.1016/S0165-1781(97)00123-6, 9481807.
43. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435. 10.1192/bjp.133.5.429, 728692.
44. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995, 166(5):654-659. 10.1192/bjp.166.5.654, 7620753.
45. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483. 10.1097/00005650-199206000-00002, 1593914.
46. Berns S, Uzelac S, Gonzalez C, Jaeger J. Methodological considerations of measuring disability in bipolar disorder: validity of the Multidimensional Scale of Independent Functioning. Bipolar Disord 2007, 9(1-2):3-10. 10.1111/j.1399-5618.2007.00305.x, 17391344.
47. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord 2005, 85(1-2):3-16. 10.1016/j.jad.2004.12.001, 15780671.
48. Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 2003, 43(9):940-949. 10.1046/j.1526-4610.2003.03184.x, 14511270.
49. Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J Affect Disord 2003, 76(1-3):127-135. 10.1016/S0165-0327(02)00080-0, 12943942.
50. Sunderland A, Harri JE, Baddeley AD. Do laboratory tests predict everyday memory?. J Verb Learn Verb Behav 1983, 22:341-357.
51. Lingjaerde O, Ahlfors U, Bech P, Dencker S, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987, 334:1-100. 10.1111/j.1600-0447.1987.tb10566.x, 2887090.
52. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 2000,
53. Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, Skeppar P, Vieta E, Scott J. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord 2005, 88(2):217-233. 10.1016/j.jad.2005.05.011, 16125784.